Hsp90 C-terminal ligands are potential new anti-cancer drugs alternative to the more studied N-terminal inhibitors. Here we report the identification of a new dihydropyrimidinone binding the C-terminus, which is not structurally related to other well-known natural and nature-inspired inhibitors of this second druggable Hsp90 site.
Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold
STROCCHIA, MARIA;TERRACCIANO, Stefania;CHINI, MARIA GIOVANNA;DAL PIAZ, FABRIZIO;LEONE, ANTONIETTA;RICCIO, Raffaele;BRUNO, Ines;BIFULCO, Giuseppe
2015-01-01
Abstract
Hsp90 C-terminal ligands are potential new anti-cancer drugs alternative to the more studied N-terminal inhibitors. Here we report the identification of a new dihydropyrimidinone binding the C-terminus, which is not structurally related to other well-known natural and nature-inspired inhibitors of this second druggable Hsp90 site.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
